Abstract Library

#3069 Functioning Pancreatic Neuroendocrine Tumors (F-pNETs): The Experience of a Tertiary Care Center of Pancreatic Surgery

Introduction: Surgery represents the optimal treatment of F-pNETs, especially if performed in high volume centers of pancreatic surgery.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Nessi C, Lenzi S, Landoni L, Bianchi B, Elio G,

Keywords: Functioning pancreatic neuroendocrine tumors, pancreatic surgery,

#3048 Somatostatin Analogs or Active Surveillance in Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors

Introduction: Non-functioning (NF), sporadic pancreatic neuroendocrine tumors (pNETs) have usually an indolent behavior, but sometimes show an unpredictable aggressiveness. Surgery is the first-choice for localized tumors >2 cm. Unresectable or metastatic lesions expressing somatostatin receptors (SSTRs) are treated with Somatostatin analogs (SSAs). No evidence of SSAs efficacy exists in tumors ≤2 cm, for which active surveillance has been proposed.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Schinzari G, Maiorano B, Rossi E, Bianchi A, Chiloiro S,

Keywords: pNET, non-functioning, sporadic, somatostatin analogs, surveillance,

#2961 Our Experience Using a New Scoring System to Detect Disease Recurrence after Curative Surgical Resection of Well-Differentiated Pancreatic Neuroendocrine Tumors

Introduction: For patients with nonfunctioning pNET  ≥20 mm in size without distant metastasis, complete surgical resection is recommended as the primary curative strategy. Effective follow‐up programs are designed to detect recurrence at an early stage, given that treatment of limited disease has the most favorable outcome. However, data on post‐curative surgical recurrence remains limited, making it challenging to determine the best follow‐up strategy and to detect the best treatment options as an adjuvant therapy for selected patients.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Mastrangelo L

Authors: Mastrangelo L, Cipressi C, Masetti M, Zanello M, Romboli A,

Keywords: nomogram, pancreatic neuroendocrine tumor, recurrence,

#2934 Vasostatin-1 Predicts Recurrence in Patients Submitted to Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)

Introduction: An association between preoperative Vasostatin-1 (VS-1) plasma level and pathological features of aggressiveness was previously reported in patients with surgically resected nonfunctioning (NF) PanNET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Andreasi V

Authors: Andreasi V, Partelli S, Manzoni M, Muffatti F, Colombo B,

Keywords: pancreatic neuroendocrine tumors, biomarkers, chromogranin A, vasostatin 1, recurrence,

#2856 Pattern of Disease Recurrence and Treatment after Radical Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)

Introduction: The risk of recurrence after radical surgery performed for pancreatic neuroendocrine tumors (PanNET) is reported between 10 and 30%. Nowadays, no adjuvant therapy is recommended for these patients and specific treatments are offered only when recurrence occurs. Nevertheless, among the available systemic and locoregional treatments, there are no specific recommendations on which the best option could be for treating recurrent disease.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Andreasi V

Authors: Andreasi V, Partelli S, Landoni L, Nessi C, Muffatti F,

Keywords: pancreatic neuroendocrine tumors, recurrence, surgery, locoregional treatment, systemic treatment,